Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.51 |
| ▸ | NPC1 | O15118 | 4/20 | 0.51 |
| ▸ | RAB9A | P51151 | 4/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | PKM | P14618 | 2/20 | 0.51 |
| ▸ | STAT3 | P40763 | 1/20 | 0.51 |
| ▸ | STAT1 | P42224 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.40 |
| ▸ | MIF | P14174 | 7/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | CYP24A1 | Q07973 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 3/20 | 0.36 |
| ▸ | BCHE | P06276 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6172839 | 1.00 | MAPT (0.51) | MAPTNPC1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL6172864 | 0.84 | MIF (0.53) | MAPTNPC1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL6172869 | 0.84 | MIF (0.53) | MAPTNPC1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL6171696 | 0.83 | MEN1 (0.41) | MAPTNPC1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL6171702 | 0.83 | MEN1 (0.41) | MAPTNPC1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL6174426 | 0.82 | MIF (0.41) | MAPTNPC1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL6172883 | 0.82 | MIF (0.41) | MAPTNPC1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL6174149 | 0.81 | MIF (0.56) | MAPTNPC1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL6174152 | 0.81 | MIF (0.56) | MAPTNPC1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL6173867 | 0.80 | MIF (0.46) | MAPTNPC1RAB9ASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0966446-B1 | BICYCLIC INHIBITORS OF PROTEIN FARNESYL TRANSFERASE | WARNER LAMBERT CO (US) | 2005-10-19 | — | — | EP | claimed |
| US-20020006936-A1 | Bicyclic inhibitors of protein farnesyl transferase | BIKKER JACK (US) | 2002-01-17 | — | — | US | claimed |
| US-6265422-B1 | ANTICANCER AGENTS; CARDIOVASCULAR DISORDERS | WARNER-LAMBERT COMPANY | 2001-07-24 | — | — | US | claimed |
| EP-0966446-A1 | BICYCLIC INHIBITORS OF PROTEIN FARNESYL TRANSFERASE | WARNER-LAMBERT COMPANY (US) | 1999-12-29 | — | — | EP | claimed |
| WO-1998034921-A1 | BICYCLIC INHIBITORS OF PROTEIN FARNESYL TRANSFERASE | WARNER-LAMBERT COMPANY (US) | 1998-08-13 | — | — | WO | claimed |
| EP-0966446-B1 | BICYCLIC INHIBITORS OF PROTEIN FARNESYL TRANSFERASE | WARNER LAMBERT CO (US) | 2005-10-19 | — | — | EP | disclosed |
| US-6528535-B2 | Anticancer agents; restenosis | WARNER-LAMBERT COMPANY | 2003-03-04 | — | — | US | disclosed |
| US-20020006936-A1 | Bicyclic inhibitors of protein farnesyl transferase | BIKKER JACK (US) | 2002-01-17 | — | — | US | disclosed |
| US-6265422-B1 | ANTICANCER AGENTS; CARDIOVASCULAR DISORDERS | WARNER-LAMBERT COMPANY | 2001-07-24 | — | — | US | disclosed |
| US-6133303-A | VARIOUS INDENE DERIVATIVES, WITH THE EXCEPTION OF 5-(2-IMIDAZOLE-1-YL-ETHOXY)INDAN-1-ONE; TREATING CANCER AND TREATING OR PREVENTING RESTENOSIS OR ATHEROSCLEROSIS | WARNER-LAMBERT COMPANY (US) | 2000-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020006936-A1 | Bicyclic inhibitors of protein farnesyl transferase | FNTA, FNTB, SREBF1 | MAPT 4469/4885NPC1 16/4885RAB9A 1910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.